The Role of Tumor Mutational Burden in Lung Cancer

Geoffrey R. Oxnard, MD; Lauren L. Ritterhouse, MD, PhD

Video Categories: PMO Interview with the Innovator Series: Volume 12 and Video Library

Drs. Goeffrey Oxnard and Lauren Ritterhouse discuss the need for validation and standardization of Tumor Mutational Burden to make it a robust biomarker, in conjunction with PD-L1, in selecting immunotherapy for their lung cancer patients.

Related Videos

September 2, 2015

Changing the Way Takeda Oncology Develops Cancer Medicines

Dixie-Lee Esseltine, MD and George Mulligan, PhD offer insight on the impact of ixazomib on Takeda Oncology’s approach to multiple myeloma care and its approach to other cancer types.

September 20, 2013

Personalized Care and the Value Proposition

Linda Bosserman discusses the issues regarding the value of personalized care